Advertisement

Topics

Guerbet LLC Company Profile

23:01 EDT 20th June 2018 | BioPortfolio

Since 1901 Guerbet Group has had a long-standing tradition as a pioneer in the research and development of medical imaging contrast media. Headquartered in Paris, France, Guerbet is a publicly traded company holding more than 20% of the European market share and 7% of the worldwide contrast media market.
The Guerbet product portfolio is marketed in 130 countries worldwide and contains contrast agents for X-ray and MRI modalities: Oxilan®, Hexabrix®(1), Dotarem®(2), Lumirem®(2), Endorem®(2) and others. Guerbet dedicates the best talent and resources to new drug development, currently having multiple agents in Phase III clinical trials.

Guerbet LLC, the U.S. subsidiary was established in February of 2002 by purchasing the assets of Oxilan from Cook®, one of the leaders in the medical device industry. Currently Guerbet LLC is responsible for the marketing, sales and distribution of Oxilan® (Ioxilan Injection), a non-ionic contrast media for diagnostic and interventional imaging. In addition, steps are underway to seek approval for new products in the U.S. market, beginning with an extracellular MR agent and an MR blood pool agent in the future.

Location

1185 West 2nd Street
Bloomington
Indiana
47403-2160
United States of America

Contact

Phone: 812-333-0059
Fax: 812-333-0084
Email: info-us@guerbet-group.com


News Articles [25 Associated News Articles listed on BioPortfolio]

Guerbet launches L─F Hydra Vision Digital Imaging System for urological imaging

Guerbet LLC USA, part of Guerbet Group, the global specialist in contrast product and solutions for medical imaging, announced the launch of the L─F Hydra Vision Digital Imaging System, a new real...

Guerbet announces acquisition of Accurate Medical Therapeutics

Guerbet, a company focused on medical imaging solutions and contrast agents, made an initial payment of about $23.4 million f -More- 

Guerbet launches L-F Hydra Vision digital urological imaging system

Guerbet LLC USA, part of Guerbet Group, has launched the L-F Hydra Vision digital imaging system, a new real-time digital X-ray imaging device developed to streamline workflow and improve efficiency i...

Guerbet licenses embolization microspheres technology from Occlugel

Guerbet SA licensed exclusive worldwide rights to Occlugel SAS's patented microsphere technology.

Global and Chinese Guerbet Alcohols Industry, 2017 Market Research Report [Report Updated: 24122017] Prices from USD $3000

The 'Global and Chinese Guerbet Alcohols Industry, 20122022 Market Research Report' is a professional and indepth study on the current state of the global Guerbet Alcohols industry with a focus on the...

Guerbet acquires microcatheter start-up Accurate Medical for up to €57mm

Guerbet SA agreed to acquire Israeli device start-up Accurate Medical Therapeutics Ltd., a developer of embolization microcatheters used in image-guided interventional radiology procedures, including ...

Guerbet announces the acquisition of a new microsphere technology to strengthen its interventional imaging range

  Acquisition of a technology developed by Occlugel, a French company specialized in the R&D of microspheres used in embolization; This new technology will round out Guerbet's Interv...

Guerbet buys Israeli mini-catheter co Accurate Medical

The French company will pay €19.5 million immediately and milestone payments. The total paid for the acquisition will not exceed €57 million.

PubMed Articles [0 Results]

None

Clinical Trials [2 Associated Clinical Trials listed on BioPortfolio]

Post-marketing Surveillance Study for Evaluation of Dotarem Safety

Guerbet conducted a non-interventional post-marketing surveillance study on its Magnetic Resonance Imaging (MRI) contrast agent Dotarem (gadoteric acid/gadoterate meglumine). The aim of th...

Post Marketing Surveillance Study for Evaluation of Efficacy and Safety of Dotarem in Magnetic Resonance Mammography

Guerbet conducted a non-interventional post-marketing surveillance study on its Magnetic Resonance Imaging (MRI) contrast agent Dotarem (gadoteric acid/gadoterate meglumine) from September...

Companies [2 Associated Companies listed on BioPortfolio]

Guerbet LLC

Since 1901 Guerbet Group has had a long-standing tradition as a pioneer in the research and development of medical imaging contrast media. Headquartered in Paris, France, Guerbet is a publicly traded ...

Simafex

Simafex is a fine chemicals company with a worldwide presence.Founded in 1959 near La Rochelle in west France, it was part of Pierre Fabre laboratories till 1987 when it joined the French pharmaceutic...

More Information about "Guerbet LLC" on BioPortfolio

We have published hundreds of Guerbet LLC news stories on BioPortfolio along with dozens of Guerbet LLC Clinical Trials and PubMed Articles about Guerbet LLC for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Guerbet LLC Companies in our database. You can also find out about relevant Guerbet LLC Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Radiology
Radiology is the branch of medicine that studies imaging of the body; X-ray (basic, angiography, barium swallows), ultrasound, MRI, CT and PET. These imaging techniques can be used to diagnose, but also to treat a range of conditions, by allowing visuali...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...


Corporate Database Quicklinks



Searches Linking to this Company Record